<DOC>
	<DOCNO>NCT00230334</DOCNO>
	<brief_summary>The purpose trial determine safety efficacy Gleevec '' idiopathic hypereosinophilic syndrome ( HES ) characterize molecular basis therapeutic benefit Gleevec '' HES .</brief_summary>
	<brief_title>Phase II Gleevec Idiopathic Hypereosinophilic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Eosinophilia</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>At study entry , absolute peripheral blood eosinophil count great upper limit normal laboratory analysis perform . Patients must symptomatic disease , e.g . sign symptom organ involvement relate eosinophilia . Examples include pulmonary , cardiac , GI , central nervous system disease , hepatomegaly , splenomegaly , skin disease . BCRABLnegative PCR . Patients imatinibnaive . Ability understand willingness sign write informed consent document . Ability swallow capsules. &amp; # xA ; Pregnant nursing woman . Patients childbearing potential must negative pregnancy test prior initiation study drug . Male female patient reproductive potential must agree employ effective barrier method birth control study 3 month follow discontinuation study drug . Serum creatinine &gt; 2.0 . Total serum bilirubin &gt; 2.0 mg/dl . AST ( SGOT ) ALT ( SGPT ) 2.5 x upper limit normal range ( ULN ) laboratory analysis perform . Presence clonal Tlymphocyte population PCR southern blotting . ECOG Performance Status Score &gt; = 3 . Busulfan within 6 week start treatment . IFNa within 14 day start treatment . Low dose cytosinearabinoside vincristine within 14 day start treatment . Hydroxyurea within 1 day start treatment . Prednisone immunosuppressive ( e.g . azathioprine , cyclosporineA ) within 14 day start treatment . AML/ALLtype induction chemotherapy within 4 week start treatment Persistent peripheral blood count toxicity grade 2 high receiving AML/ALLtype induction chemotherapy . Treatment investigational agent within 28 day start treatment . History noncompliance medical regimen . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure ( Grade 3 / 4 New York Heart Association Criteria ) , unstable angina pectoris cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . History HIVpositivity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>